Filtered By:
Drug: Taxotere

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 2210 results found since Jan 2013.

Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
J Clin Med. 2022 May 15;11(10):2783. doi: 10.3390/jcm11102783.ABSTRACTMetastatic castration-resistant prostate cancer (mCRPC) is the ultimately lethal form of prostate cancer. Docetaxel chemotherapy was the first life-prolonging treatment for mCRPC; however, the standard maximally tolerated dose (MTD) docetaxel regimen is often not considered for patients with mCRPC who are older and/or frail due to its toxicity. Low-dose metronomic chemotherapy (LDMC) is the frequent administration of typically oral and off-patent chemotherapeutics at low doses, which is associated with a superior safety profile and higher tolerability th...
Source: Clinical Prostate Cancer - May 28, 2022 Category: Cancer & Oncology Authors: Shruti Parshad Amanjot K Sidhu Nabeeha Khan Andrew Naoum Urban Emmenegger Source Type: research

Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel ’s activity by suppressing the NF-kB signaling pathway
Ubiquitin-specific protease 8 (USP8) has been recently reported to be involved in tumorigenesis. Prostate cancer (PCa) is the most diagnosed malignancy among men, but USP8’s role in PCa is not yet investigated comprehensively. Therefore, the PCa cell lines DU145 and PC3 were transfected with USP8 siRNA or overexpressing vector together with or without docetaxel. The silencing USP8 and docetaxel treatment reduced cell viability and migration and promoted apoptosis. In contrast, USP8 knockdown was found to enhance docetaxel antitumor activity. In contrast, increased cell viability and migration were noticed upon USP8 overe...
Source: Frontiers in Oncology - October 20, 2022 Category: Cancer & Oncology Source Type: research

Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer
We examined paired tissues from Taiwanese patients and observed that 65.09% and 68.25% of patients exhibited TSTD1 hypomethylation and overexpression, respectively. A significant correlation was found between TSTD1 hypomethylation and overexpression in Taiwanese (74.2%, p = 0.040) and Western (88.0%, p < 0.001) cohorts. High expression of TSTD1 protein was observed in 68.8% of Taiwanese and Korean breast cancer patients. Overexpression of TSTD1 in tumors of breast cancer patients was significantly associated with poor 5-year overall survival (p = 0.021) and poor chemotherapy response (p = 0.008). T47D cells treated with...
Source: Frontiers in Oncology - November 7, 2022 Category: Cancer & Oncology Source Type: research

Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review
CONCLUSIONS: This SLR of the Asian data on therapies for advanced PC from the pivotal and real-world studies confirms similar efficacy and safety outcomes, consistent with the results from the pivotal clinical trials. These findings will help clinicians make better treatment decisions in clinical practice for patients with advanced/metastatic PC.PMID:36407784 | PMC:PMC9666834 | DOI:10.1177/17588359221131525
Source: Adv Data - November 21, 2022 Category: Epidemiology Authors: Marniza Saad Rainy Umbas Edmund Chiong Ravindran Kanesvaran Source Type: research

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
CONCLUSIONS: Pembrolizumab plus lenvatinib is indicated for patients with unselected pretreated metastatic endometrial cancer and pembrolizumab monotherapy is a preferred option for patients with MMRd/MSI-H tumors.PMID:36950270 | PMC:PMC10026109 | DOI:10.1177/17588359231157633
Source: Adv Data - March 23, 2023 Category: Epidemiology Authors: Anna V Tinker Neesha C Dhani Prafull Ghatage Deanna McLeod Vanessa Samou ëlian Stephen A Welch Alon D Altman Source Type: research

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
Conclusion: This study demonstrates that lipegfilgrastim 6 mg is as effective as pegfilgrastim in reducing neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.Trial RegistrationEudra EEACTA200901599910. https://www.clinicaltrialsregister.eu/ctr-search/search?query=XM22-03The study protocol, two global amendments (Nos. 1 and 2), informed consent documents, and other appropriate study-related documents were reviewed and approved by the Ministry of Health of Ukraine Central Ethics Committee and local independent ethics committees (IECs).
Source: BMC Cancer - August 14, 2013 Category: Cancer & Oncology Authors: Igor BondarenkoOleg GladkovReiner ElaesserAnton BuchnerPeter Bias Source Type: research

Abstract P3-13-07: Does treatment response to new agents differ between visceral and non-visceral metastatic breast cancer: A systematic literature review of registration trials
Conclusions: Using a systemic literature search, we stratified published studies of the last 20 years considering HER2 and hormone receptor status with respect to metastasis pattern. In the subgroup analyses, we did not find any significant differences in response rates for visceral vs. non-visceral metastasis. For targeted therapies based on a biomarker, there seems to be a beneficial effect of combination therapies regarding OS in visceral disease. At the present time, metastasis localization should not be used as a predictive marker for choice of systemic therapy in mBC. Citation Format: Rachel Würstlein, Maximilian Ba...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Wurstlein, R., Bardenhewer, M., Konig, A., Kolben, T., Gehring, C., Harbeck, N. Tags: Poster Session Abstracts Source Type: research

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report.
CONCLUSION: addition of docetaxel into ADT has beneficial effects in terms of overall survival and progression free survival in patients with non-castrate resistant metastatic prostate cancer. PMID: 28450658 [PubMed - in process]
Source: Acta medica Indonesiana - May 1, 2017 Category: Internal Medicine Tags: Acta Med Indones Source Type: research

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence
ConclusionsThe treatment of mCRPC was associated with significant cost. In the post-docetaxel setting, single fraction radiotherapy and enzalutamide were considered cost-effective in most studies. Generic ZA was the recommended bone-targeting therapy.
Source: PharmacoEconomics - July 29, 2017 Category: Health Management Source Type: research

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
Conclusion and Relevance: Checkpoint inhibitors plus chemotherapy compared with chemotherapy, are associated with significantly prolonged OS and PFS in first-line therapy in NSCLC. In the low PDL1 subgroups the benefit was statistically significant only in the pembrolizumab backbone trials. The findings of this meta-analysis could assist in the design and interpretation of future trials and in economic analyses. Introduction Lung cancer is the leading cause of cancer death worldwide. Non-small-cell lung cancer (NSCLC) accounts for almost 85% of all cases (1). The prognosis of NSCLC patients remains quite unsatisfacto...
Source: Frontiers in Oncology - April 15, 2019 Category: Cancer & Oncology Source Type: research

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
Conclusions: Nivolumab and pembrolizumab have promising outcomes with tolerable AEs and drug-related deaths in patients with relapsed or refractory lymphoma. Pembrolizumab caused less any grade AEs like fatigue and rash than nivolumab. Patients with HL got better response than NHL. Introduction Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor mainly expressed on activated T cells, natural killer cells, and B cells (Ishida et al., 1992). The PD-L1 and PD-L2 are its known ligands, which interact with PD-1 on T cells and prevent T-cell activation and proliferation. PD-L1 is expressed on macropha...
Source: Frontiers in Pharmacology - April 30, 2019 Category: Drugs & Pharmacology Source Type: research

Overcoming the challenges in the treatment of glioblastoma via nanocarrier based drug delivery approach
CONCLUSION: Broad research is still needed so that these nanocarriers can be used clinically for the welfare of mankind, in the management of glioblastoma, in near future.PMID:34082676 | DOI:10.2174/1381612827666210603152056
Source: Current Pharmaceutical Design - June 4, 2021 Category: Drugs & Pharmacology Authors: Saurabh Mittal Javed Ali Sanjula Baboota Source Type: research